Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with prostate cancer (a specific type called adenocarcinoma) confirmed by a lab test, and you do not have a type called "pure small cell carcinoma"
- Your prostate cancer has spread to other parts of the body, is no longer responding to hormone-lowering treatments, and your PSA level is 4 ng/mL or higher at the time of screening
- Your cancer has gotten worse within the past 6 months, shown by a rising PSA level, new or growing tumours on scans, or 2 or more new spots appearing on a bone scan
- You have already tried at least 2 approved treatments for advanced prostate cancer (beyond basic hormone therapy), including at least one newer hormone-blocking drug such as abiraterone, enzalutamide, apalutamide, or darolutamide, and your cancer has continued to progress or you could not tolerate those treatments
Who may not be able to join:
- You have received certain approved biological cancer treatments within the last 3 weeks, or you are still experiencing side effects from a previous treatment
- You have received certain biological or immune-based cancer treatments too recently before the start of this trial (confirm with trial site for exact timing)
- You have previously received a therapy that specifically targets a protein called PSMA — though if you received a PSMA-targeting radioactive treatment (such as 177Lu-PSMA-617), you may still be eligible if at least 12 weeks have passed since your last dose
- You currently need to take regular high-dose steroid medication (more than 10 mg of prednisone per day or a similar anti-inflammatory drug)
- You have a significant autoimmune disease (where the immune system attacks the body) that required strong immune-suppressing treatment within the last 5 years
- You have had brain inflammation, meningitis, an uncontrolled seizure disorder, or a significant brain or nerve condition in the past year (mild memory problems that do not affect daily life may be acceptable — confirm with trial site)
- You have an uncontrolled HIV, Hepatitis B, or Hepatitis C infection, or a condition that weakens your immune system
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Dose-Limiting Toxicities (DLTs); Incidence and severity of Treatment-Emergent Adverse Events (TEAEs); Incidence and severity of Serious Adverse Events (SAEs); Incidence and severity of Adverse Events of Special Interest (AESIs); REGN4336 monotherapy concentrations in serum; REGN4336 concentrations in serum in combination with REGN5678; Composite Response Rate (CRR) of ≥50% decline of prostate specific antigen (PSA) and/or confirmed radiographic response of complete response (CR) or partial response (PR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.